Belite Bio, Inc. ADR (BLTE) AI Stock Analysis

• Market Cap: $6.79B
• Dividend Yield: N/A
• Average Volume (3M): 64.23K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.00
• Revenue Growth: N/A
• EPS Growth: -73.27%
• Country: US
• Employees: 25
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.38
• Shares Outstanding: 37,514,630
• 10 Day Avg. Volume: 75,810
• 30 Day Avg. Volume: 64,229
• PEG Ratio: 63.44
• Price to Book (P/B): 13.21
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -65.58
• Enterprise Value/Market Cap: 0.93
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: -129.39
• 1Y Price Target: $215.29
• Price Target Upside: 24.23% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 7
• EPS Forecast (FY): -2.15
• Revenue Forecast (FY): $30.00M

• Rating: 62 Neutral
• Price Target: $199.00 ▲(14.83% Upside)
• Action: Reiterated Date: 12/30/25
• Date: Action: Reiterated 12/30/25

BLTE’s score is driven by solid balance-sheet strength but weighed down by pre-revenue financials and rising cash burn. Technicals are bullish with strong trend support, while valuation remains challenging due to ongoing losses. The latest earnings call was a net positive on regulatory/clinical progress and improved liquidity, despite higher expenses and losses.

Positive Factors

Conservative balance sheet / low leverage

Extremely low debt versus sizable equity gives durable financial flexibility for a clinical-stage biotech. This reduces refinancing and solvency risk across multi-year trials, supports strategic collaborations or M&A optionality, and lessens near-term pressure to sell assets or cut programs.

Material cash runway from recent financings

A large, recent cash balance meaningfully extends runway to complete pivotal trials and regulatory filings. This liquidity reduces the immediacy of capital markets dependence, enabling management to focus on evidence generation and commercialization planning without urgent financing-driven program cuts.

Pivotal clinical and regulatory progress

Completion of Phase III enrollments plus regulatory acceptances are durable de-risking events: they strengthen a first-in-class positioning for tinlarebant, support multi-region approval pathways, and materially increase the likelihood of future revenue if pivotal data and filings remain favorable.

Negative Factors

Pre-revenue with widening losses

No product revenue through multiple years means profitability depends entirely on successful trials and launches. Widening losses indicate sustained cash consumption and negative returns on equity, implying persistent dilution risk and reliance on external funding until commercialization.

Accelerating operating cash burn

Rapidly increasing negative operating cash flow shortens the effective runway absent new capital, raising execution risk for multi-year studies. Persistent negative free cash flow heightens vulnerability to market conditions when raising funds and can force program delays or unfavorable financing terms.

Rising expenses and share-based compensation

Sharply higher R&D and G&A, including significant non-cash share-based comp, inflate operating losses and can persist into commercialization, pressuring margins. Rising structural overhead increases the funding requirement and the probability of further equity dilution to sustain growth and operations.

Belite Bio, Inc. ADR Business Overview & Revenue Model

Company Description

Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the eye to reduce the accumulation of toxic vitamin A by-products in ocular tissue that is in phase 3 clinical trial. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.

How the Company Makes Money

Belite Bio primarily makes money by developing and commercializing pharmaceutical products. The company generates revenue through strategic partnerships and collaborations with other pharmaceutical companies and research institutions, where it may receive upfront payments, milestone payments, and royalties on sales of successfully developed drugs. Additionally, Belite Bio may seek funding through grants and government programs to support its research and development activities, which are critical to advancing its product candidates through clinical trials and towards market approval.

Belite Bio, Inc. ADR Financial Statement Overview

Summary

Strong balance-sheet conservatism (minimal debt vs. sizable equity) supports flexibility, but the company is still pre-revenue with widening multi-year losses and accelerating cash burn, raising ongoing funding and execution risk.

Income Statement

BLTE remains a pre-revenue biotech with $0 revenue across 2020–2024, so profitability is entirely driven by operating spend rather than commercialization. Losses have widened meaningfully over time (net loss roughly -$5.8M in 2020 to -$36.1M in 2024), indicating rising R&D and operating expenses. A modest positive is that 2024 net loss was only slightly worse than 2023, but the overall trajectory is still sharply negative with no revenue base yet.

Balance Sheet

The balance sheet looks conservative on leverage: total debt is minimal in 2024 (~$0.5M) against a large equity base (~$145.8M), implying very low financial risk from borrowing. Assets and equity expanded substantially from 2022 to 2024, consistent with successful capital raising. The key weakness is that returns on equity are negative due to ongoing losses, and the business will likely continue consuming equity capital until revenue arrives.

Cash Flow

Cash generation is weak, with operating cash flow and free cash flow consistently negative and the cash burn accelerating (operating cash flow about -$4.4M in 2020 to -$29.2M in 2024). Free cash flow tracks closely to net loss, suggesting limited non-cash offsets and a business model still in heavy investment mode. While negative cash flow is common for development-stage biotech, the increasing burn rate raises execution and funding-timing risk.

Breakdown	TTM	Dec 2024	Dec 2023	Mar 2023	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	-198.00K	-30.00K	0.00
EBITDA	-49.04M	-35.67M	-31.20M	-12.43M	-9.64M	-5.73M
Net Income	-49.38M	-36.14M	-31.63M	-12.65M	-9.67M	-5.75M
Balance Sheet
Total Assets	156.41M	152.13M	94.64M	44.27M	18.35M	25.74M
Cash, Cash Equivalents and Short-Term Investments	0.00	145.15M	88.16M	42.09M	17.34M	25.62M
Total Debt	0.00	537.00K	886.00K	866.00K	31.81M	31.81M
Total Liabilities	6.52M	6.31M	4.21M	2.77M	33.44M	32.78M
Stockholders Equity	149.88M	145.82M	90.43M	41.50M	-15.09M	-7.04M
Cash Flow
Free Cash Flow	0.00	-29.39M	-29.90M	-11.85M	-7.55M	-4.46M
Operating Cash Flow	0.00	-29.23M	-29.84M	-11.46M	-7.47M	-4.44M
Investing Cash Flow	0.00	-110.57M	-63.00K	-394.00K	-56.00K	-20.00K
Financing Cash Flow	0.00	83.59M	75.96M	36.96M	-583.00K	28.06M

Belite Bio, Inc. ADR Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 173.30
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BLTE, the sentiment is Neutral. The current price of 173.3 is below the 20-day moving average (MA) of 179.73, above the 50-day MA of 169.59, and above the 200-day MA of 105.22, indicating a neutral trend. The MACD of 1.90 indicates Positive momentum. The RSI at 47.87 is Neutral, neither overbought nor oversold. The STOCH value of 28.20 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for BLTE.

Belite Bio, Inc. ADR Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
KNSA	69 Neutral	$3.52B	53.89	11.73%	―	55.68%	―
HRMY	69 Neutral	$1.65B	23.98	20.75%	―	21.13%	50.86%
BLTE	62 Neutral	$6.79B	-69.12	-32.30%	―	―	-73.27%
DNLI	55 Neutral	$3.12B	-5.65	-45.69%	―	―	-5.30%
BEAM	54 Neutral	$2.60B	-34.27	-8.11%	―	-84.07%	-157.71%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CNTA	48 Neutral	$3.54B	-14.82	-60.46%	―	117.83%	-18.91%

Belite Bio, Inc. ADR Corporate Events

Belite Bio Completes Global Enrollment in DRAGON II Tinlarebant Trial for Stargardt Disease

On January 27, 2026, Belite Bio announced it has completed enrollment of 60 adolescent patients, including 15 in Japan, in its global Phase 2/3 DRAGON II trial of tinlarebant for Stargardt disease type 1, a 24‑month randomized, double‑masked, placebo‑controlled study spanning Japan, the United States and the United Kingdom. The milestone, achieved after tinlarebant previously met the primary endpoint in the pivotal Phase 3 DRAGON trial with a 36% reduction in lesion growth, advances Belite’s registration strategy in both the U.S. and Japan and keeps the company on track to file a U.S. New Drug Application in the first half of 2026, reinforcing its position as a front-runner in developing the first disease-modifying treatment for STGD1 and potentially strengthening its standing in the broader retinal disease market.

The most recent analyst rating on (BLTE) stock is a Buy with a $195.00 price target. To see the full list of analyst forecasts on Belite Bio, Inc. ADR stock, see the BLTE Stock Forecast page.

Belite Bio Prices $350 Million ADS Offering to Boost Drug Development

On December 1, 2025, Belite Bio announced the pricing of a $350 million underwritten public offering of American Depositary Shares, each representing one ordinary share, at $154.00 per ADS. The offering, expected to close on December 3, 2025, aims to support commercialization preparation, pipeline development, and general corporate purposes. This move is significant for Belite Bio as it seeks to strengthen its market position and advance its drug development efforts, particularly for its lead candidate, Tinlarebant.

The most recent analyst rating on (BLTE) stock is a Buy with a $194.00 price target. To see the full list of analyst forecasts on Belite Bio, Inc. ADR stock, see the BLTE Stock Forecast page.

Belite Bio Reports Increased Cash Reserves Amid Rising R&D Costs

Belite Bio, Inc. released its unaudited interim condensed consolidated financial statements for the nine months ending September 30, 2025. The company reported a significant increase in cash and cash equivalents, rising from $31.7 million at the end of 2024 to $157 million by September 2025. Despite this, the company experienced a net loss of $52.3 million during the same period, primarily due to increased research and development expenses. The financial results reflect Belite Bio’s ongoing investment in its pipeline, which could impact its market positioning and stakeholder confidence as it continues to focus on long-term growth and innovation.

The most recent analyst rating on (BLTE) stock is a Buy with a $185.00 price target. To see the full list of analyst forecasts on Belite Bio, Inc. ADR stock, see the BLTE Stock Forecast page.

Belite Bio Announces Public Offering of ADSs to Fund Expansion

On December 1, 2025, Belite Bio, Inc announced the commencement of an underwritten public offering of American Depositary Shares, each representing one ordinary share. The proceeds from this offering are intended for commercialization preparation, pipeline development, and general corporate purposes. The offering is subject to market conditions, and its completion is not guaranteed, highlighting potential impacts on the company’s operational expansion and market positioning.

The most recent analyst rating on (BLTE) stock is a Buy with a $185.00 price target. To see the full list of analyst forecasts on Belite Bio, Inc. ADR stock, see the BLTE Stock Forecast page.

Belite Bio Reports Breakthrough Phase 3 Results for Stargardt Disease Treatment

On December 1, 2025, Belite Bio announced positive results from its Phase 3 DRAGON trial for Tinlarebant, a treatment for Stargardt disease. The trial demonstrated a significant reduction in retinal lesion growth, marking a potential breakthrough for a condition with no current approved treatments. The successful trial positions Belite Bio to file for regulatory approval in 2026, potentially offering new hope to over 50,000 affected individuals in the U.S. The findings underscore the company’s commitment to addressing unmet medical needs and could significantly impact the treatment landscape for retinal disorders.

The most recent analyst rating on (BLTE) stock is a Buy with a $154.00 price target. To see the full list of analyst forecasts on Belite Bio, Inc. ADR stock, see the BLTE Stock Forecast page.

Belite Bio Announces Q3 2025 Results and Key Trial Progress

On November 10, 2025, Belite Bio reported its financial results for the third quarter of 2025 and provided a corporate update. The company completed enrollment in its pivotal phase 3 PHOENIX trial for geographic atrophy and the DRAGON trial for Stargardt disease, with final topline data expected in Q4 2025. Regulatory agencies in China and the UK have accepted applications for Tinlarebant based on interim analysis results. Financially, Belite Bio completed a $15 million registered direct offering and a $125 million private placement, strengthening its position to advance Tinlarebant towards regulatory milestones.

The most recent analyst rating on (BLTE) stock is a Buy with a $132.00 price target. To see the full list of analyst forecasts on Belite Bio, Inc. ADR stock, see the BLTE Stock Forecast page.